Targeting pheochromocytoma/paraganglioma with polyamine inhibitors

Autor: Felix Beuschlein, David Taïeb, Sergei G. Tevosian, Raymond J. Bergeron, Laura Shelton, Kenneth Cusi, Srilaxmi Kalavalapalli, Karel Pacak, Arthur S. Tischler, Abhishek Jha, Soumya Luthra, James A. Bibb, Shashank Jatav, Chris Beecher, Jose G. Trevino, Kimi Kong, Fernando Bril, Prodip Bose, Arielle Click, Susan Richter, Matthias Kroiss, Priyanka Gupta, Robert Hromas, Douglas P. Lee, Austin Kirby, Katharina Langton, Yiling Xu, Mercedes Robledo, Timothy J. Garrett, Kriti Kriti, James F. Powers, Daniel Plant, Henri J L M Timmers, Bruna Calsina, Joy Guingab-Cagmat, Graeme Eisenhofer, Hans K. Ghayee, Heather M. Hatch, Sudhir K. Rai

Publikováno v: Metabolism
Metabolism, Elsevier, 2020, 110, pp.154297. ⟨10.1016/j.metabol.2020.154297⟩
Metabolism-Clinical and Experimental, 110
Metabolism, 2020, 110, pp.154297. ⟨10.1016/j.metabol.2020.154297⟩

Background Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors that are mostly benign. Metastatic disease does occur in about 10% of cases of PCC and up to 25% of PGL, and for these patients no effective therapies are availab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce52549c75b861138e9ad0db9381927f
https://hal.archives-ouvertes.fr/hal-02890700